Carregant...
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Resistance to targeted therapeutics is a key issue limiting the long-term utility of these medications in the management of molecularly selected subsets of cancer patients, including patients with non-small cell lung cancer harboring oncogenic alterations affecting EGFR, ALK and other genes. Bypass...
Guardat en:
| Publicat a: | Ann Transl Med |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5253284/ https://ncbi.nlm.nih.gov/pubmed/28164089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2016.12.09 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|